Neurogene Inc.

NASDAQ:NGNE

Biotechnology

Healthcare
$23.14 +2.47%

+$0.76 today

Market cap
$365.67M
Beta
2.04
P/E (TTM)
-7.1
EPS (TTM)
-$4.42
52W Low $14.65High $37.27

Volume 0.25M

Average 0.16M

NGNE Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Neurogene Inc.NASDAQ: NGNE

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash turns positive

Q1 FY2026 net change in cash was $20.32M, compared with -$65.82M a year earlier. Trailing-twelve-month net change in cash was $53.39M.

Context

  • Net change in cash increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly net change in cash holds near $20.32M or moves back toward the trailing-twelve-month quarterly average of $13.35M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$20.32M-38.1% QoQ
Last fiscal yearDec 2025
-$32.74M+177.6% YoY
LTMMar 2026
$53.39M+167.3% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+130.9%——
1 year+177.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
(32.74M) USD
Year-over-year change
-177.6%

Net Change in Cash vs competitors

How NGNE compares with its peers on the latest reported figures

  • NGNE's LTM Mar 2026 net change in cash of $53.39M is the 3rd largest of the 8 companies compared; the peer median is $5.19M.
  • Its year-over-year change of +167.3% is the 2nd highest of 8, against a peer median of +0.1%.
NGNE Competitors Peer median
Net Change in Cash for NGNE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TSHATaysha Gene Therapies, Inc.LTM Jun 2026$140.21M +0.1%—2556.2%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$68.48M -51.8%-4.0%77.6%
NGNENeurogene Inc.LTM Mar 2026$53.39M +167.3%——
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$42.86M +125.8%——
ALECAlector, Inc.LTM Mar 2026$38.99M +212.8%—211.7%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$34.32M -49.8%-30.5%94.0%
MGTXMeiraGTx Holdings plcLTM Mar 2026$5.19M +110.1%+19.1%6.5%
DSGNDesign Therapeutics, Inc.LTM Mar 2026$897K -94.3%-72.4%—
Peer median (excluding NGNE) $5.19M+0.1%-17.2%94.0%

Competitors are the stored peer set for NGNE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(50.52M)(55.19M)(36.32M)(75.14M)(90.35M)
Depreciation & Amortization947K3.2M3.3M3.25M3.09M
Deferred Income Tax00(105K)00
Stock-Based Compensation896K1.25M1.42M8.32M14.18M
Change in Working Capital1.6M(2.7M)(4.02M)(5.96M)268K
Accounts Receivables00000
Inventory00000
Accounts Payables2.98M(3.61M)667K(77K)627K
Other Working Capital(1.39M)912K(4.69M)(5.88M)(359K)
Other Non-Cash Items679K608K(15.69M)(1.07M)(4.37M)
Operating Cash Flow(46.4M)(52.82M)(51.42M)(70.6M)(77.17M)
Capital Expenditures(18.37M)(2.23M)(321K)(808K)(1.18M)
Acquisitions (Net)00000
Purchases of Investments000(198.45M)(269.51M)
Sales of Investments005M74M284.7M
Other Investing Activities0020.96M00
Investing Cash Flow(18.37M)(2.23M)25.64M(125.26M)14M
Debt Repayment0(1K)(29K)(52K)(61K)
Common Stock Issued287K73K92.34M189.59M30.38M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00168K(5.47M)0
Financing Cash Flow51.06M66.53M92.48M184.07M30.43M
Effect of Forex Changes00000
Net Change in Cash(13.71M)11.48M66.7M(11.79M)(32.74M)
Free Cash Flow(64.77M)(55.05M)(51.74M)(71.41M)(78.36M)

Neurogene Inc.

NASDAQ:NGNE

Intrinsic Alpha fair value

Locked

Current Price

$23.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.